AI Article Synopsis
- * out of 2489 SpA patients examined, only 36 (1.4%) were diagnosed with AFLD, and those patients were typically older, more likely to be male, heavy smokers, and had longer disease durations.
- * it emphasizes the need for careful diagnosis, as AFLD symptoms can mimic tuberculosis, especially in males and those with a history of prolonged disease.
Article Abstract
Objective: The rate of pleuroparenchymal involvement in patients with SpA varies widely, from 0% to 85%. The most common form is apical fibrobullous disease (AFLD). The aim of this study was to determine the incidence of AFLD and associated factors in SpA patients under and/or planned to start biologic DMARDs (bDMARDs) therapy.
Methods: The records of 3021 SPA patients registered with HUR-BIO who had indication of bDMARDs between 2010 and 2021 were scanned. The study included 2489 patients with at least one chest radiograph (X-ray). Patient demographics, comorbidities, laboratory data, bDMARDs used, baseline DASs, and purified protein derivative and/or QuantiFERON test results before initiation of bDMARDs were recorded.
Results: Of the 2489 patients, 36 (1.4%) were found to have AFLD by X-ray and/or CT. The mean disease duration was 11.7 (7.1) years. Patients with AFLD were more likely to be male [28 (77.8%) vs 1321 (53.9%), P = 0.004], older [56.3 (10.5) years vs 44.8 (11.4) years, P < 0.001], heavy smokers [27 (79.4%) vs 1468 (60.9%), P = 0.028] and have had longer disease duration [17. 7 (9.7) years vs 11.6 (7) years, P = 0.001]. QuantiFERON positivity was higher in the AFLD group [9 (36%) vs 309 (16.1%), P = 0.013]. While treatment with adalimumab was less preferred in those with AFLD, treatment with etanercept was more frequently preferred.
Conclusion: As the radiological findings of AFLD can be confused with those of tuberculosis, special attention should be paid to differentiating between tuberculosis and the disease in males and in patients who have had long disease duration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986796 | PMC |
| http://dx.doi.org/10.1093/rheumatology/kead361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sjögren's Syndrome and Ankylosing Spondylitis Association: A Case-Based Review.
Curr Rheumatol Rev
November 2024
Department of Rheumatology Military Hospital, Tunis, Tunisia.
Introduction: Unlike restrictive pulmonary function and apical fibrobullous disease, diffuse interstitial lung disease is scarce in patients with ankylosing spondylitis (AS). We present a systematic review of the association between AS and SS. We also report a new case of SS revealed by interstitial lung disease in AS patients treated with tumor necrosis factor (TNF) inhibitors.
View Article and Find Full Text PDFApical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication.
Rheumatology (Oxford)
April 2024
Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
Article Synopsis
- * out of 2489 SpA patients examined, only 36 (1.4%) were diagnosed with AFLD, and those patients were typically older, more likely to be male, heavy smokers, and had longer disease durations.
- * it emphasizes the need for careful diagnosis, as AFLD symptoms can mimic tuberculosis, especially in males and those with a history of prolonged disease.
A Case of Post-COVID-19 Fibrosis Mimicking Thoracic Manifestation of Ankylosing Spondylitis.
Acta Med Litu
March 2022
Muğla Sıtkı Koçman University, Faculty of medicine, Department of Pulmonology, Mentese/Mugla/Turkey.
The most common thoracic manifestation form of ankylosing spondylitis is apical fibrocystic changes. It is also known as apical fibrobullous disease (AFBD). The patient was diagnosed with ankylosing spondylitis before 9 years.
View Article and Find Full Text PDFApical fibrobullous lung disease in ankylosing spondylitis: case report and literature review.
Eur Clin Respir J
June 2022
Respiratory Medicine Department, Hospital de São Bernardo, Centro Hospitalar de Setúbal EPE, Setúbal, Portugal.
Ankylosing spondylitis (AS) is associated with several unique pulmonary manifestations such as apical fibrobullous disease (AFBD), which is a rare extra-spinal complication, predominantly occurring in advanced disease. Infectious complications and differential diagnosis of cavitated lung lesions may be challenging, particularly in patients already submitted to immunosuppression. In this report, we present a low body-mass-index 47-year-old male patient, ex-smoker, with AS and severe joint involvement, medicated in the past with anti-TNF-α therapy, who was diagnosed with AFBD and developed pulmonary tuberculosis and later chronic cavitary pulmonary aspergillosis.
View Article and Find Full Text PDFPulmonary manifestations of ankylosing spondylitis.
Clin Chest Med
September 2010
Department of Medicine, National Jewish Health, Denver, CO 80206, USA.
Ankylosing spondylitis, a chronic multisystem inflammatory disorder, can present with articular and extra-articular features. It can affect the tracheobronchial tree and the lung parenchyma, and respiratory complications include chest wall restriction, apical fibrobullous disease with or without secondary pulmonary superinfection, spontaneous pneumothorax, and obstructive sleep apnea. Ankylosing spondylitis is a common cause of pulmonary apical fibrocystic disease; early involvement may be unilateral or asymmetrical, but most cases eventually consist of bilateral apical fibrobullous lesions, many of which are progressive with coalescence of the nodules, formation of cysts and cavities, fibrosis, and bronchiectasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!